How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Buy
53
ADCT Quote, Financials, Valuation and Earnings
Last price:
$3.25
Seasonality move
:
-27.31%
Day range:
$3.02 - $3.39
52-week range:
$1.05 - $4.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.56x
P/B ratio:
--
Volume:
622K
Avg. volume:
915.2K
1-year change:
-12.3%
Market cap:
$332.2M
Revenue:
$70.8M
EPS (TTM):
-$1.45
Analysts' Opinion
-
Consensus RatingADC Therapeutics SA has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.20, ADC Therapeutics SA has an estimated upside of 144.78% from its current price of $3.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $3.35.
Fair Value
-
According to the consensus of 4 analysts, ADC Therapeutics SA has 144.78% upside to fair value with a price target of $8.20 per share.
ADCT vs. S&P 500
-
Over the past 5 trading days, ADC Therapeutics SA has overperformed the S&P 500 by 23.97% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ADC Therapeutics SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ADC Therapeutics SA has grown year-over-year revenues for 3 quarters straight. In the most recent quarter ADC Therapeutics SA reported revenues of $23M.
Earnings Growth
-
ADC Therapeutics SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ADC Therapeutics SA reported earnings per share of -$0.36.
Enterprise value:
251.4M
EV / Invested capital:
--
Price / LTM sales:
4.56x
EV / EBIT:
--
EV / Revenue:
3.32x
PEG ratio (5yr expected):
-0.07x
EV / Free cash flow:
-1.84x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$70.3M
Return On Assets:
-46.15%
Net Income Margin (TTM):
-197.64%
Return On Equity:
--
Return On Invested Capital:
-4172.63%
Operating Margin:
-122.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $182.4M | $68.6M | $75.8M | $18.1M | $23M | |
| Gross Profit | $179.7M | $63.6M | $70.3M | $15.5M | $21M | |
| Operating Income | -$132.7M | -$148.3M | -$124.4M | -$33.4M | -$28.2M | |
| EBITDA | -$146.2M | -$131.8M | -$95.6M | -$32.4M | -$25.4M | |
| Diluted EPS | -$2.52 | -$2.77 | -$1.45 | -$0.56 | -$0.36 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $393.2M | $487.7M | $380M | $290.2M | $258M | |
| Total Assets | $461.7M | $581.9M | $467.7M | $308M | $272.5M | |
| Current Liabilities | $41.4M | $70.8M | $81.1M | $63M | $57.8M | |
| Total Liabilities | $163.7M | $419.2M | $430M | $502.4M | $510.8M | |
| Total Equity | $298M | $162.7M | $37.7M | -$194.4M | -$238.2M | |
| Total Debt | $39.4M | $95M | $110.5M | $113.2M | $113.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$119.8M | -$147.4M | -$136.1M | -$44.1M | -$56.3M | |
| Cash From Investing | -$255K | -$2.7M | -$600K | -$531K | -$264K | |
| Cash From Financing | -$214K | $73.8M | $97M | $356K | $271K | |
| Free Cash Flow | -$120.4M | -$150.1M | -$136.7M | -$44.6M | -$56.6M | |
ADCT
Sector
Market Cap
$332.2M
$34.5M
Price % of 52-Week High
81.11%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-12.3%
-35.15%
Beta (5-Year)
1.895
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.02
200-day SMA
Buy
Level
$2.21
Bollinger Bands (100)
Buy
Level
1.26 - 2.86
Chaikin Money Flow
Sell
Level
-9.4M
20-day SMA
Buy
Level
$2.96
Relative Strength Index (RSI14)
Buy
Level
61.70
ADX Line
Buy
Level
20.09
Williams %R
Sell
Level
-4.1916
50-day SMA
Buy
Level
$2.62
MACD (12, 26)
Buy
Level
0.11
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-621.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.288)
Sell
CA Score
(Annual)
Level (-6.4709)
Buy
Beneish M-Score
(Annual)
Level (-2.8406)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (8.8566)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Stock Forecast FAQ
In the current month, ADCT has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADCT average analyst price target in the past 3 months is $8.20.
-
Where Will ADC Therapeutics SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that ADC Therapeutics SA share price will rise to $8.20 per share over the next 12 months.
-
What Do Analysts Say About ADC Therapeutics SA?
Analysts are divided on their view about ADC Therapeutics SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ADC Therapeutics SA is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is ADC Therapeutics SA's Price Target?
The price target for ADC Therapeutics SA over the next 1-year time period is forecast to be $8.20 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ADCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ADC Therapeutics SA is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ADCT?
You can purchase shares of ADC Therapeutics SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ADC Therapeutics SA shares.
-
What Is The ADC Therapeutics SA Share Price Today?
ADC Therapeutics SA was last trading at $3.25 per share. This represents the most recent stock quote for ADC Therapeutics SA. Yesterday, ADC Therapeutics SA closed at $3.35 per share.
-
How To Buy ADC Therapeutics SA Stock Online?
In order to purchase ADC Therapeutics SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
77
VBTX alert for Jul 15
Veritex Holdings [VBTX] is down 3.26% over the past day.
Buy
72
MNPR alert for Jul 15
Monopar Therapeutics [MNPR] is down 8.6% over the past day.
Buy
56
NBIS alert for Jul 15
Nebius Group NV [NBIS] is up 2.98% over the past day.
